Prevalence of prostate cancer following an initial negative MRI-fusion biopsy of the prostate from 2018-2022: A single-center retrospective descriptive cohort.

Jose Leuel A ONGKEKO; Mark C CELLONA

Return

Prevalence of prostate cancer following an initial negative MRI-fusion biopsy of the prostate from 2018-2022: A single-center retrospective descriptive cohort.

Author: Jose Leuel A. ONGKEKO ^{1
,

2} ; Mark C. CELLONA ³
Author Information

1. Institute of Urology, St Luke’s Medical Center, Quezon City, Metro Manila, NCR, Philippines
2. Institute of Urology, St Luke’s Medical Center Global City, Taguig, Metro Manila, NCR, Philippines
3. St Luke’s Medical Center Global City, Taguig, Metro Manila, NCR, Philippines
Publication Type:Journal Article, Original
Keywords: Negative Prostate Biopsy; Multiparametric Prostate Imaging
MeSH: Human; Prostate Cancer; Prostatic Neoplasms
From: Philippine Journal of Urology 2025;35(1):9-12
CountryPhilippines
Language:English
Abstract: OBJECTIVES
To determine the incidence of prostate cancer on follow up after an initial negative MRI- fusion biopsy of the prostate, and to determine the change in PSA and MRI results on follow-up.
METHODS
MRI-fusion prostate biopsy registry from 2018 to 2022 was obtained then histopathology, MRI results, and PSA results were obtained. Repeat PSA and MRI results at extracted at 3 years. PSA mean, range, and change were then determined. MRI results were extracted to determine progression, regression, or persistence.
RESULTS
A total of 670 prostate biopsies were done in the study period, of which 70 were included. PSA on biopsy 9.93 (3.35 – 55.0) with corresponding PIRADS lesions 3, 4, and 5 (n=55, n=19, and n=6). No patient was subsequently diagnosed with prostate cancer on follow-up. PSA mean 7.03, 6.44, 5.27, and 6.07 at 3years interval from biopsy. Repeat prostate MRI showed persistence in 1 and regression in 6 patients.
CONCLUSION
After a negative MRI-fusion biopsy of the prostate no patient developed prostate cancer with a general decrease in trend in PSA and MRI on follow-up. These patients may have longer interval follow-up periods given the clinical scenario but would be best to test this method in prospective trials first.